Program
P-CD19CD20-ALLO1 Cells
Its studies are mostly in Multiple Sclerosis · Lupus Erythematosus, Systemic, led by Hoffmann-La Roche.
Furthest: phase 1, since May 14, 20252 company-led studies, 1 open or runningNext primary completion: Aug 31, 2032 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 21 open or running | phase 1since May 14, 2025 | May 14, 2025 | Aug 31, 2032phase 1 · NCT07008378 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2025First studies: 2 phase 1 studiesFirst studyNCT06984341, NCT07008378
Ahead
- Aug 31, 2032Primary completion: phase 1 study in Multiple SclerosisNCT07008378
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07008378Multiple Sclerosis · United States | 1 | Active, not recruiting | Aug 31, 2032 | 60 |
| NCT06984341Lupus Erythematosus, Systemic · United States | 1 | Withdrawn | Nov 1, 2033 | 0 |
How it is read
Names in the registry
- “P-CD19CD20-ALLO1 Cells”, 2 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.